Navigation Links
Boehringer Ingelheim Renews and Expands License to NextBio Research Platform
Date:7/9/2013

SANTA CLARA, Calif., July 9, 2013 /PRNewswire/ -- NextBio, whose Big Data technology enables users to apply genomic data from disparate sources in novel and useful ways across life sciences research, today announced that Boehringer Ingelheim has signed a multi-year renewal agreement to the NextBio Research Platform. The new agreement also expands the user base for NextBio across Boehringer Ingelheim's global research organization.

(Logo: http://photos.prnewswire.com/prnh/20130402/SF86976LOGO)

"Boehringer Ingelheim is one of the world's 20 leading pharmaceutical companies and has been a user of NextBio Research for the past year," said Saeid Akhtari, NextBio President and Chief Executive Officer. "This expanded license and broadened access to the NextBio Research platform is a strong endorsement of our technology's value for enabling life scientists to quickly examine and understand their data in the context of published research worldwide.

"NextBio Research provides a comprehensive platform for exploratory, preclinical and early translational research in drug discovery and biotechnology research," Mr. Akhtari added. "Integrating proprietary analysis results with extensive curated content, NextBio enhances researchers' ability to design experiments, test hypotheses and validate results, leading to better target analysis, understanding of disease mechanisms, and analysis of results across species."

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

Social responsibility is a central element of Boehringer Ingelheim's culture. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavours.

In 2012, Boehringer Ingelheim achieved net sales of about 14.7 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 22.5% of its net sales.

About NextBio

NextBio provides a state of the art scientific platform to aggregate and interpret large quantities of molecular and other life sciences data for research and clinical applications. NextBio's platform integrates data from multiple repositories and diverse technologies by means of a unique correlation engine, which pre-computes billions of significant connections between disparate public and proprietary clinical and experimental data. This feature enables interpretation of an individual's molecular data. It also provides translational researchers the ability to look across the clinical and molecular data of entire populations for clinical trial stratification and selection, hypotheses generation, and biomarker discovery. NextBio Clinical, which recently passed an independent HIPAA audit, is designed for seamless integration with existing clinical and research systems. Backed by highly scalable, Big Data technology, it is capable of analyzing petabytes of data. NextBio's platform is delivered as a SaaS (Software as a Service) solution resulting in quick deployment and rapid return on investment.

Today, NextBio is used by researchers and clinicians in over 50 top commercial and academic institutions including the National Institute of Health, The University of Southern California, Sanford-Burnham Medical Research Institute, Sanofi, Pfizer, Novartis, Celgene, Eli Lilly, Genzyme, Johnson & Johnson, Merck, Regeneron, GlaxosmithKline, Harvard Medical School, Scripps Research Institute, Stanford University, University of California at Berkeley, Takeda and many others. To learn more about NextBio, please visit our website at http://www.nextbio.com.


'/>"/>
SOURCE NextBio
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies
2. Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference
3. Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
4. ASCO 2013: Boehringer Ingelheim to Present Data Across Multiple Cancers, Including Different Treatment Settings for Advanced NSCLC
5. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
6. Boehringer Ingelheim to Announce Pivotal Phase 3 Hepatitis C Data at the International Liver Congress
7. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
8. Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment
9. Boehringer Ingelheim Announces Interim Results Evaluating Virologic Response Rates in HCV/HIV Co-Infected Patients Treated with Faldaprevir
10. Boehringer Ingelheim Cares Foundation Launches Online Giving Report
11. Boehringer Ingelheim Presents Efficacy Data for Tiotropium in Symptomatic Asthma Patients in Relation to Allergic Status
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... de fevereiro de 2016  A Proliant Biologicals ... de soroalbumina bovina (BSA -- Bovine Serum ... na Ilha Norte da Nova Zelândia, em Feilding. ... na fábrica da Proliant nos EUA, localizada em ... e instalação dos equipamentos foram feitos de forma ...
(Date:2/11/2016)... Transformational M&A achieved through NPS and Dyax acquisitions and the ... achieved through NPS and Dyax acquisitions and the announced combination ... through NPS and Dyax acquisitions and the announced combination with ... robust pipeline in Shire , s history   ... pipeline in Shire , s history   ...
(Date:2/11/2016)... , February 11, 2016 Breast Cancer ... the Asia-Pacific (APAC) breast cancer market ... $3.4 billion by 2021, at a Compound Annual Growth Rate ... Asia-Pacific Markets to 2021 - states that the ... considerable expansion from $1.9 billion in 2014 to $3.4 billion ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... 11, 2016 , ... Greenfield Insurance Group in Orange City, ... the people of their local community. The agency pledges to select a new ... hope is to bring awareness to important local causes with fundraising and other ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... practice Village Family Practice , will be presenting at the 2016 HIMSS ... Las Vegas, Nev. , During his session, “ Coding for Care: Using ...
(Date:2/11/2016)... ... 11, 2016 , ... The annual list showcases the 20 Most Promising SharePoint ... dedication and commitment to the SharePoint ecosystem. A panel of experts and members ... is to recognize and promote technology entrepreneurship. , The survey was made at ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... the American Academy of Dermatology Annual Meeting at the Walter E. Washington Convention ... raise awareness for both the condition of hyperhidrosis (excessive sweating) and its treatment ...
(Date:2/11/2016)... ... February 11, 2016 , ... Food Labeling for American ... and wellness best practices in the past couple of decades, and food manufacturers ... Heart Month, which acts as an exceptional opportunity to revise food labels and ...
Breaking Medicine News(10 mins):